medigraphic.com
Órgano Oficial del Instituto Nacional de Pediatría

2017, Number 1

<< Back Next >>

Acta Pediatr Mex 2017; 38 (1)

Statins treatment in pediatric patients with steroid resistant nephrotic syndrome. A two case reports

Sánchez-García C, Bailón-Ortega AA, Zaltzman-Girshevich S

Language: Spanish
References: 23
Page: 26-32
PDF size: 620.33 Kb.


ABSTRACT

The nephrotic syndrome is defined by the association of proteinuria, hypoalbuminemia, hyperlipidemia and edema. 80% of the pediatric patients with primary nephrotic syndrome respond to steroid therapy; the remaining 20% require associate other drugs to achieveremission (cyclophosphamide, cyclosporine). The hyperlipidemia in the nephrotic syndrome is due both to an increased synthesis and decreased elimination of blood lipids; being the direct cause of this the proteinuria. The hyperlipidemia increases cardiovascular risk and glomerular damage. Based on this, the persistent hyperlipidemia in the steroid-resistant nephrotic syndrome should be treated. The HMG-CoA reductase inhibitors have shown immunomodulatory, antiinflammatory and anti-proliferative effect. Therefore, the role of statins in the nephrotic syndrome goes beyond their lipid-lowering effect.
We present two cases of pediatric patients diagnosed with steroidresistant nephrotic syndrome and its evolution during treatment with cyclosporine and statins.


REFERENCES

  1. Avner ED, Harmon WE, Niaudet P, Yoshikawa N. Pediatric nephrology. 6th ed. Berlin: Springer; c 2009. 667p.

  2. Peña A, Bravo J, Melgosa M, Fernández C, Meseguer C, Espinoza L, et al. Steroid-resistant nephrotic syndrome: long-term evolution after sequential therapy. Pediatr Nephrol. 2007;22(11):1875-1880.

  3. Loeffler K, Gowrishankar M, Yiu V. Tacrolimus therapy in pediatric patients with treatment-resistant nephrotic syndrome. Pediatr Nephrol. 2004;19(3):281-287.

  4. Niaudet P. Treatment of childhood steroid-resistant idiopathic nephrosis with a combination of cyclosporine and prednisone. French Society of Pediatric Nephrology. J Pediatr. 1994;125(6 Pt 1):981-986.

  5. Hodson EM, Willis NS, Craig JC. Interventions for idiopathic steroid-resistant nephrotic syndrome in children. Cochrane Database Syst Rev. 2010 Nov; 10(11):CD003594. doi: 10.1002/14651858.CD003594.pub4.

  6. Kaysen GA, Davies RW. Reduction in proteinuria attenuates hyperlipidemia n the nephrotic syndrome. J Am Soc Nephrol. 1990;1(5 Suppl 2):S75-S79.

  7. Kaysen GA, Gambertoglio J, Felts J, Hutchison FN. Albumin synthesis, albuminuria and hyperlipemia in nephrotic patients. Kidney Int. 1987;31(6):1368-1376.

  8. Thabet MA, Salcedo JR, Chan JC. Hyperlipidemia in childhood nephrotic syndrome. Pediatr Nephrol. 1993;7(5):559- 566.

  9. Querfeld U. Should hyperlipidemia in children with the nephrotic syndrome be treated? Pediatr Nephrol. 1999;13(1):77-84.

  10. Duplaga BA. Treatment of childhood hypercholesterolemia with HMG-CoA reductase inhibitors. Ann Pharmacother. 1999;33(11):1224-1227.

  11. García-de-la-Puente S. Arredondo-García JL, Gutiérrez- Castrellón P, Bojorquez-Ochoa A, Maya ER, Pérez-Martínez Mdel P. Efficacy of simvastatin in children with hyperlipidemia secondary to kidney disorders. Pediatr Nephrol. 2009;24(6):1205-1210. doi: 10.1007/s00467-099-1128-7.

  12. Buemi M, Nostro L, Crasci E, Barillà A, Consentino V, Aloisi C, et al. Statins in nephrotic syndrome: a new weapon against tissue injury. Med Res Rev. 2005;25(6):587-609.

  13. Endo A. The Discovery and development of HMC-CoA reductase inhibitors. J Lipid Res. 1992;33(11):1569-1582.

  14. Massy ZA, Ma JZ, Louis TA, Kasiske BL. Lipid-lowering therapy in patients with renal disease. Kidney Int. 1995;48(1):188-198.

  15. Sanjad SA, al-Abbad A, al-Shorafa S. Management of hyperlipidemia in children with refractory nephrotic syndrome: the effect of statin therapy. J Pediatr. 1997;130(3):470-474.

  16. Coleman JE, Watson AR. Hyperlipidaemia, diet and simvastatin therapy in steroid-resistant nephrotic syndrome of childhood. Pediatr Nephrol. 1996;10(2):171-174.

  17. Prata MM, Noqueira AC, Pinto JR, Correira AM, Vicente O, Rodrigues MC, et al. Long-term effect of lovastatin on lipoprotein profile in patients with primary nephrotic syndrome. Clin Nephrol. 1994;41(5):277-283.

  18. Ponticelli C, Rizzoni G, Edefonti A, Altieri P, Rivolta E, Rinaldi S, el al. A randomized trial of cyclosporine in steroid-resistant idiopathic nephrotic syndrome. Kidney Int. 1993;43(6):1377-1384.

  19. Cattran DC, Appel GB, Hebert LA, Hunsicker LG, Pohl MA, Hoy WE, et al. A randomized trial of cyclosporine in patients with steroid-resistant focal segmental glomerulosclerosis. North America Nephrotic Syndrome Study Group. Kidney Int. 1999;56(6):2220-2226.

  20. Vaziri ND, Liang K, Azad H. Effect of cyclosporine on HMGCoA reductase, cholesterol 7alpha-hydroxylase, LDL receptor, HDL receptor, VLDL receptor, and lipoprotein lipase expressions. J Pharmacol Exp Ther. 2000;294(2):778-783.

  21. Hirano T, Kawamura T, Fukuda S, Kohsaka S, Yoshikawa N, Yoshida M, et al. Implication of cholesterol in cyclosporine pharmacodynamics in minimal change nephrotic syndrome. Clin Pharmacol Ther. 2003;74(6):581-590.

  22. Ito S, Machida H, Inaba A, Harada T, Okuyama K, Nakamura T, et al. Amelioration of steroids and cyclosporine-resistant nephrotic syndrome by pravastatin. Pediatr Nephrol. 2007;22(4):603-606.

  23. Kong X, Yuan H, Fan J, Li Z, Wu T, Jiang L. Lipid-lowering agents for nephrotic syndrome. Cochrane Database Syst Rev. 2013;10(12):CD005425. doi: 10.1002/14651858. cd005425.pub2.




2020     |     www.medigraphic.com